Sign In
Buy IMRN
$1.15
+0.0900 (+8.49%)
At Close: Jun 22, 2026
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
06:00am, Wednesday, 05'th Jun 2024
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our
Immuron CEO Steven Lydeamore to present at Peak Sky High
06:00am, Friday, 31'st May 2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief E
Immuron Board Changes
06:00am, Friday, 31'st May 2024
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has
Immuron Limited to Present at the Emerging Growth Conference
06:00am, Tuesday, 07'th May 2024
MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual a
Immuron Director Resignation
06:00am, Friday, 03'rd May 2024
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou
Immuron to host Live Virtual Event
06:00am, Monday, 15'th Apr 2024
MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief
Immuron Travelan® sales continued strong growth
06:00am, Wednesday, 10'th Apr 2024
Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AU
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
06:00am, Thursday, 07'th Mar 2024
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy
Immuron Presentation Australian Biologics Festival 2024
06:00am, Wednesday, 21'st Feb 2024
MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Researc
Immuron achieves record Travelan® sales
06:00am, Tuesday, 13'th Feb 2024
Highlights: Travelan® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan® YTD Jan 2024 sales $2.1 million USA Travelan® YTD Jan 2024 sales $0.6
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
06:00am, Thursday, 08'th Feb 2024
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief E
Immuron achieves record half yearly Travelan® sales
06:00am, Tuesday, 16'th Jan 2024
Highlights: Record half yearly Travelan® sales of $2,334,969 Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales 51% higher than pre-pandemic period H1, FY20 sales MELBOURNE,
Immuron Clinical Trials Update
06:00am, Friday, 22'nd Dec 2023
Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
06:00am, Monday, 04'th Dec 2023
Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunt
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
06:33am, Tuesday, 28'th Nov 2023
MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholder
